Cellectis SA (NASDAQ:CLLS) shares rose 2.7% during trading on Monday . The company traded as high as $27.00 and last traded at $26.59, with a volume of 64,684 shares trading hands. The stock had previously closed at $25.90.

CLLS has been the subject of a number of research analyst reports. Jefferies Group restated a “buy” rating on shares of Cellectis SA in a research note on Friday, August 5th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $65.00 price objective on shares of Cellectis SA in a research note on Wednesday, July 27th. Zacks Investment Research cut Cellectis SA from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Cellectis SA in a research note on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $43.60.

The stock’s 50-day moving average price is $26.53 and its 200 day moving average price is $27.19. The company’s market capitalization is $980.40 million.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.